Scarica l'app Stockscreener
4.81
4.66%
-0.235
Dopo l'orario di chiusura:
4.89
0.08
+1.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
Savara Inc CCO Braden Parker Withholds 29,323 Shares for RSU Tax Settlement - Kalkine Media
Form 4 Savara Inc For: 25 September By Investing.com - Investing.com Nigeria
Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster? - RTTNews
Savara Inc (YB4P.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Savara Pharmaceuticals stock holds near its yearly low - AD HOC NEWS
Savara, Inc. (SVRA) Stock Analysis: Exploring a Potential 101.80% Upside in Biotech Investment - DirectorsTalk Interviews
SVRA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Commercial Biotech Keeps Focus on Pipeline Execution - careplusvn.com
Savara (SVRA) Institutional Ownership 2026 - MarketBeat
SVRA Q2 2026 Earnings: Wider-than-Expected Loss of $0.16 Per Share, Shares Rise 2.98% on Pipeline OptimismConsensus Miss Rate - dars.gov.et
When Can We Expect A Profit From Savara Inc. (NASDAQ:SVRA)? - moomoo.com
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - simplywall.st
Savara stock holds steady as investors focus on lead lung therapy - ad-hoc-news.de
Savara Grants Equity Awards to Eight New Employees - MyChesCo
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Savara (SVRA) Results at a Glance: Profit Per Share Falls Below Its Benchmark for This Review; Market Response: Shares Finish 0.72% Higher for the Current SessionFinancial Health Score - careplusvn.com
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)? - simplywall.st
Savara presents molgramostim data at ERS Congress in September By Investing.com - Investing.com Canada
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 - Yahoo Finance
Savara (SVRA) Stock: Ends Up by 1.82% at $5.59 in the Current Update; Level Watch: the $5.31 to $5.87 Range Remains in Focus in the Latest SessionRetail Volume - dars.gov.et
Savara (SVRA) Trading: Posts a 1.82% Gain to $5.59 in Latest Trading; Next Test: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateWyckoff Spring - dars.gov.et
Savara Announces New Employment Inducement GrantAugust 20, 2026 - BioSpace
Savara (SVRA) Quarterly Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Response: Shares Move 3.91% Higher for the Current SessionEarnings Outlook Update - dars.gov.et
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11 - Moomoo
Savara (SVRA) Advances 2.09% to $5.38 as Aerosol Therapy Momentum BuildsStock Analysis - vinanet.vn
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Pipeline InvestmentPeak Earnings Alert - vinanet.vn
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11Triple Top - vinanet.vn
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA - MarketBeat
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Savara - MarketBeat
Savara (NASDAQ:SVRA) Stock Price Down 5.4%What's Next? - MarketBeat
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings - marketbeat.com
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
Savara Inc. (SVRA) Advances 1.17% as Rare Disease Focus Draws Continued Interest — Resistance at $5.91 in SightPrice Momentum Stocks - Vinanet
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Revenue Weighted - Vinanet
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
SAVARA Q2 EPS USD -0.16 - Moomoo
Savara Q2 loss widens to $40M on surging commercial costs - scanx.trade
Savara Inc (SVRA) Advances MOLBREEVI Launch Amid High Price-to-S - GuruFocus
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Savara Inc. Announces Q2 2026 Financial Results with Increased Net Losses - Kalkine Media
Savara Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Q2 loss widens as operating expenses rise - TradingView
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary - TradingView
BRIEF-Savara Q2 Net Income USD -40.228 Million - TradingView
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC - MarketBeat
Savara Inc (YB4P.SG) recent insider transactions - au.finance.yahoo.com
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 88.90% Potential Upside - DirectorsTalk Interviews
Savara investors brace for earnings ahead of crucial FDA review By Investing.com - Investing.com Nigeria
Savara (SVRA) to Announce Quarterly Earnings on Wednesday - MarketBeat
SVRA Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):